Attached files
file | filename |
---|---|
S-1/A - S-1/A AMENDMENT NO 2 - DNIB UNWIND, INC. | d579945ds1a.htm |
EX-3.4 - EX-3.4 - DNIB UNWIND, INC. | d579945dex34.htm |
EX-10.12 - EX-10.12 - DNIB UNWIND, INC. | d579945dex1012.htm |
EX-10.14 - EX-10.14 - DNIB UNWIND, INC. | d579945dex1014.htm |
EX-10.17 - EX-10.17 - DNIB UNWIND, INC. | d579945dex1017.htm |
EX-10.15 - EX-10.15 - DNIB UNWIND, INC. | d579945dex1015.htm |
EX-10.16 - EX-10.16 - DNIB UNWIND, INC. | d579945dex1016.htm |
EX-10.13 - EX-10.13 - DNIB UNWIND, INC. | d579945dex1013.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Amendment No. 2 to Registration Statement No. 333-190566 of our report dated June 28, 2013, relating to the consolidated financial statements of BIND Therapeutics Inc. (formerly known as BIND Biosciences, Inc.) and subsidiaries appearing in the Prospectus, which is a part of such Registration Statement, and to the reference to us under the heading Experts in such Prospectus.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
August 28, 2013